Hematopoietic stem cell gene therapy for the treatment of SYNGAP1‐related non‐specific intellectual disability
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3717 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Joseph S Anderson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of California Davis, Sacramento, CA, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Hematopoietic Stem Cell Transplantation, Intellectual Disability. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SynGAP Research Fund.
Abstract (Originalsprache)
Background
Synaptic Ras GTPase activating protein 1 (SYNGAP1)‐related non‐specific intellectual disability is a neurodevelopmental disorder caused by an insufficient level of SynGAP1 resulting in a dysfunction of neuronal synapses and presenting with a wide array of clinical phenotypes. Hematopoietic stem cell gene therapy has the potential to deliver therapeutic levels of functional SynGAP1 to affected neurons upon transduction of hematopoietic stem and progenitor cells with a lentiviral vector.
Methods
As a novel approach toward the treatment of SYNGAP1, we have generated a lentiviral vector expressing a modified form of SynGAP1 for transduction of human CD34+ hematopoietic stem and progenitor cells. The gene‐modified cells were then transplanted into adult immunodeficient SYNGAP1+/− heterozygous mice and evaluated for improvement of SYNGAP1‐related clinical phenotypes. Expression of SynGAP1 was also evaluated in the brain tissue of transplanted mice.
Results
In our proof‐of‐concept study, we have demonstrated significant improvement of SYNGAP1‐related phenotypes including an improvement in motor abilities observed in mice transplanted with the vector transduced cells because they displayed decreased hyperactivity in an open field assay and an increased latency to fall in a rotarod assay. An increased level of SynGAP1 was also detected in the brains of these mice.
Conclusions
These early‐stage results highlight the potential of this stem cell gene therapy approach as a treatment strategy for SYNGAP1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of California Davis, Sacramento, CA, USA.
ORCID-Profile: Joseph S Anderson
Förderung
- SynGAP Research Fund
Zitieren
APA
Anderson, J. S., Lodigiani, A. L., Barbaduomo, C. M., & Beegle, J. R. (2024). Hematopoietic stem cell gene therapy for the treatment of SYNGAP1‐related non‐specific intellectual disability. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3717
Vancouver
Anderson JS, Lodigiani AL, Barbaduomo CM, Beegle JR. Hematopoietic stem cell gene therapy for the treatment of SYNGAP1‐related non‐specific intellectual disability. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3717
BibTeX
@article{Anderson2024,
author = {Anderson, Joseph S and Lodigiani, Alyse L and Barbaduomo, Camilla M and Beegle, Julie R},
title = {Hematopoietic stem cell gene therapy for the treatment of SYNGAP1‐related non‐specific intellectual disability},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3717}
}
EUVIMED